Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1972 1
1982 2
1983 3
1984 3
1985 1
1986 1
1988 1
1989 3
1990 2
1991 1
1992 4
1993 4
1994 7
1995 4
1996 7
1997 5
1998 7
1999 4
2000 3
2001 5
2002 9
2003 9
2004 16
2005 19
2006 18
2007 28
2008 41
2009 42
2010 40
2011 48
2012 48
2013 75
2014 88
2015 95
2016 78
2017 96
2018 117
2019 141
2020 168
2021 154
2022 181
2023 150
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

1,566 results

Results by year

Filters applied: . Clear all
Page 1
Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, Ramirez FD, Harnett DT, Merdad A, Almufleh A, Weng W, Abdel-Razek O, Fernando SM, Kyeremanteng K, Bernick J, Wells GA, Chan V, Froeschl M, Labinaz M, Le May MR, Russo JJ, Hibbert B. Mathew R, et al. Among authors: weng w. N Engl J Med. 2021 Aug 5;385(6):516-525. doi: 10.1056/NEJMoa2026845. N Engl J Med. 2021. PMID: 34347952 Clinical Trial.
Viral evasion of PKR restriction by reprogramming cellular stress granules.
Gao P, Liu Y, Wang H, Chai Y, Weng W, Zhang Y, Zhou L, Ge X, Guo X, Han J, Yang H. Gao P, et al. Among authors: weng w. Proc Natl Acad Sci U S A. 2022 Jul 19;119(29):e2201169119. doi: 10.1073/pnas.2201169119. Epub 2022 Jul 11. Proc Natl Acad Sci U S A. 2022. PMID: 35858300 Free PMC article.
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, Tamaresis J, Chinnasamy H, Ehlinger Z, Reynolds W, Lynn R, Rotiroti MC, Gkitsas N, Arai S, Johnston L, Lowsky R, Majzner RG, Meyer E, Negrin RS, Rezvani AR, Sidana S, Shizuru J, Weng WK, Mullins C, Jacob A, Kirsch I, Bazzano M, Zhou J, Mackay S, Bornheimer SJ, Schultz L, Ramakrishna S, Davis KL, Kong KA, Shah NN, Qin H, Fry T, Feldman S, Mackall CL, Miklos DB. Spiegel JY, et al. Among authors: weng wk. Nat Med. 2021 Aug;27(8):1419-1431. doi: 10.1038/s41591-021-01436-0. Epub 2021 Jul 26. Nat Med. 2021. PMID: 34312556 Free PMC article. Clinical Trial.
1,566 results